search
Back to results

Web-based Collaborative Care Intervention Study (WBCCI)

Primary Purpose

Cancer, Depression, Fatigue

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Stepped collaborative care intervention
Enhanced Usual Care
Sponsored by
University of Pittsburgh
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Cancer focused on measuring Collaborative care intervention, Cancer, Depression, Palliative care, Quality of life, Fatigue, Pain

Eligibility Criteria

21 Years - 100 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Patients:

  • biopsy and/or radiograph proven diagnosis of hepatocellular carcinoma,cholangiocarcinoma, gallbladder carcinoma or breast, ovarian, or colorectal cancer with liver metastases with a life expectancy of at least one year;
  • age >21 years;
  • no evidence of thought disorder, delusions, or active suicidal ideation is observed or reported.

Caregivers:

  • a spouse or cohabitating intimate partner of an advanced cancer patient being evaluated at the UPMC's Liver Cancer Center and
  • age >21 years

Exclusion Criteria:

Patients:

  • age < 21 years,
  • lack of fluency in English,
  • evidence of thought disorder, delusions, hallucinations, or suicidal ideation.

Caregivers:

  • lack of fluency in English; and
  • evidence of thought disorder, delusions, hallucinations, or suicidal ideation.

Sites / Locations

  • UPMC East
  • The University of Pittsburgh's Medical Center Passavant Hospital
  • University of Pittsburgh Medical Center Mercy
  • University of Pittsburgh's Medical Center Montefiore Hospital
  • UPMC Presbyterian
  • UPMC St. Margaret
  • UPMC Horizen

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Stepped collaborative care intervention

Enhanced Usual Care

Arm Description

The 'Stepped Collaborative Care Intervention' includes at least biweekly contact from a care coordinator by phone and face to face visits occurring approximately every 2 months, and 24 hour 7 day a week access to a website that was specifically designed during the pilot study for advanced cancer patients from socioeconomically disadvantaged backgrounds.

Patients randomized to the 'Enhanced Usual Care' arm receive their usual care from their medical team. However, if the patient scores in the clinical range on one or more of the three symptoms s/he will receive education about the symptom and be referred to the appropriate health care provider for further treatment in their community. The care coordinator will follow up with the patient after 3 weeks to assess barriers to treatment and assist further with accessing treatment if needed.

Outcomes

Primary Outcome Measures

Quality of life (QoL)
Functional Assessment of Cancer Therapy - General (FACT-G) questionnaire

Secondary Outcome Measures

serum Interleukin (IL)-6,(mg/L)
Blood sample collection and process
serum Cancer Antigen 19-9 (u/ml)
Blood sample collection and process
serum carcinoembryonic antigen (u/ml)
Blood sample collection and process
serum Alpha feta protein (u/ml)
Blood sample collection and process
Caregivers' stress
Caregiver Quality of Life Scale- Cancer, Perceived Stress Scale
Caregivers' depression
Center for Epidemiological Studies- Depression
dyadic adjustment
Dyadic Adjustment Scale
Caregiver's blood pressure
Blood pressure readings
Caregiver's Body Mass Index
Caregiver's height and weight calculations in inches and pounds using BMI calculator
Caregiver's serum Interleukin-6
Blood sample collection and process
Caregiver's metabolic syndrome
The caregiver meets or does not meet the American Heart Association criteria for metabolic syndrome
Depression
Center for Epidemiological Studies- Depression
Fatigue
Functional Assessment of Cancer Therapy -fatigue
Pain level
Brief Pain Inventory
serum Interleukin IL-1beta,(mg/L)
cytokine
serum Tumor necrosis factor-alpha ((mg/L)
cytokine
serum Inteferon-gamma ((mg/L)
cytokine

Full Information

First Posted
October 14, 2016
Last Updated
September 15, 2023
Sponsor
University of Pittsburgh
search

1. Study Identification

Unique Protocol Identification Number
NCT02939755
Brief Title
Web-based Collaborative Care Intervention Study
Acronym
WBCCI
Official Title
Collaborative Care Intervention for Cancer Patients and Their Family Caregivers
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Completed
Study Start Date
December 1, 2016 (Actual)
Primary Completion Date
July 1, 2023 (Actual)
Study Completion Date
July 1, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Pittsburgh

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
To test the efficacy of a web-based stepped collaborative care intervention to reduce symptoms of depression, pain, and fatigue and improve health-related quality of life (HRQL) in advanced cancer patients and to reduce stress and depression, and fewer CVD risk factors in caregivers.
Detailed Description
The investigators will enroll patients at two UPMC sites: Montefiore Hospital, an academic medical center, and Passavant Hospital, a community based hospital. Based on our sample size estimate the investigators will have at least 364 patients and caregivers with complete data at 12 months follow up. The patient and caregiver will be randomly assigned to one of two arms (intervention versus enhanced usual care) stratified by gender and vessel invasion. Because these factors are the two most robust prognostic factors in this patient population. At 6 and 12 months after enrollment, follow-up questionnaires and blood draws will be performed for patients and caregivers. The stepped WBCC intervention includes at least biweekly contact from a care coordinator by phone and face to face visits occurring approximately every 2 months, and 24 hour 7 day a week access to a website. Patients randomized to the "enhanced usual care" arm receive their usual care from their medical team. However, if the patient scores in the clinical range on one or more of the three symptoms s/he will receive education about the symptom and be referred to the appropriate health care provider for further treatment in their community. The care coordinator will follow up with the patient after 3 weeks to assess barriers to treatment and assist further with accessing treatment if needed. Intervention fidelity (e.g., consistency across care coordinators) will be reduced by requiring the care coordinators to follow a 300 page manual and providing standardized training by the PI who is a clinical psychologist. Dr. Steel (PI) has received training and certification from the American Psycho-Oncology Society in the design and analysis of psycho-oncology clinical trials and intervention fidelity. The study investigators will not prescribe any medications but rather make recommendations to the patient's oncologist, PCP, psychiatrist, or pain management specialist who will be free to accept or reject the recommendations by the study team. Medication type, dosage, and adherence to medication (e.g., self-report and pharmacy refills) will be recorded for patients in the WBCC intervention and enhanced usual care arms.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cancer, Depression, Fatigue, Pain
Keywords
Collaborative care intervention, Cancer, Depression, Palliative care, Quality of life, Fatigue, Pain

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
459 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Stepped collaborative care intervention
Arm Type
Experimental
Arm Description
The 'Stepped Collaborative Care Intervention' includes at least biweekly contact from a care coordinator by phone and face to face visits occurring approximately every 2 months, and 24 hour 7 day a week access to a website that was specifically designed during the pilot study for advanced cancer patients from socioeconomically disadvantaged backgrounds.
Arm Title
Enhanced Usual Care
Arm Type
Active Comparator
Arm Description
Patients randomized to the 'Enhanced Usual Care' arm receive their usual care from their medical team. However, if the patient scores in the clinical range on one or more of the three symptoms s/he will receive education about the symptom and be referred to the appropriate health care provider for further treatment in their community. The care coordinator will follow up with the patient after 3 weeks to assess barriers to treatment and assist further with accessing treatment if needed.
Intervention Type
Behavioral
Intervention Name(s)
Stepped collaborative care intervention
Other Intervention Name(s)
treatment
Intervention Description
Using website that was specifically designed for advanced cancer patient, collaborative with treatment from health professional
Intervention Type
Behavioral
Intervention Name(s)
Enhanced Usual Care
Other Intervention Name(s)
control
Intervention Description
usual care from health providers
Primary Outcome Measure Information:
Title
Quality of life (QoL)
Description
Functional Assessment of Cancer Therapy - General (FACT-G) questionnaire
Time Frame
change from baseline at 6 and 12 months
Secondary Outcome Measure Information:
Title
serum Interleukin (IL)-6,(mg/L)
Description
Blood sample collection and process
Time Frame
change from baseline at 6 months and 12 months
Title
serum Cancer Antigen 19-9 (u/ml)
Description
Blood sample collection and process
Time Frame
change from baseline at 6 months and 12 months
Title
serum carcinoembryonic antigen (u/ml)
Description
Blood sample collection and process
Time Frame
change from baseline at 6 months and 12 months
Title
serum Alpha feta protein (u/ml)
Description
Blood sample collection and process
Time Frame
change from baseline at 6 months and 12 months
Title
Caregivers' stress
Description
Caregiver Quality of Life Scale- Cancer, Perceived Stress Scale
Time Frame
change from baseline at 6 and 12 months
Title
Caregivers' depression
Description
Center for Epidemiological Studies- Depression
Time Frame
change from baseline at 6 and 12 months
Title
dyadic adjustment
Description
Dyadic Adjustment Scale
Time Frame
change from baseline at 6 and 12 months
Title
Caregiver's blood pressure
Description
Blood pressure readings
Time Frame
change from baseline at 6 and 12 months
Title
Caregiver's Body Mass Index
Description
Caregiver's height and weight calculations in inches and pounds using BMI calculator
Time Frame
change from baseline at 6 and 12 months
Title
Caregiver's serum Interleukin-6
Description
Blood sample collection and process
Time Frame
change from baseline at 6 and 12 months
Title
Caregiver's metabolic syndrome
Description
The caregiver meets or does not meet the American Heart Association criteria for metabolic syndrome
Time Frame
change from baseline at 6 and 12 months
Title
Depression
Description
Center for Epidemiological Studies- Depression
Time Frame
change from baseline at 6 and 12 months
Title
Fatigue
Description
Functional Assessment of Cancer Therapy -fatigue
Time Frame
change from baseline at 6 and 12 months
Title
Pain level
Description
Brief Pain Inventory
Time Frame
change from baseline at 6 and 12 months
Title
serum Interleukin IL-1beta,(mg/L)
Description
cytokine
Time Frame
change from baseline at 6 and 12 months
Title
serum Tumor necrosis factor-alpha ((mg/L)
Description
cytokine
Time Frame
change from baseline at 6 and 12 months
Title
serum Inteferon-gamma ((mg/L)
Description
cytokine
Time Frame
change from baseline at 6 and 12 months
Other Pre-specified Outcome Measures:
Title
Health care utilization
Description
Emergency Room visits, 30- and 90-day readmissions, length of stay in the hospital.
Time Frame
1 year
Title
Health care costs
Description
activity based costs
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
100 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients: biopsy and/or radiograph proven diagnosis of hepatocellular carcinoma,cholangiocarcinoma, gallbladder carcinoma or breast, ovarian, or colorectal cancer with liver metastases with a life expectancy of at least one year; age >21 years; no evidence of thought disorder, delusions, or active suicidal ideation is observed or reported. Caregivers: a spouse or cohabitating intimate partner of an advanced cancer patient being evaluated at the UPMC's Liver Cancer Center and age >21 years Exclusion Criteria: Patients: age < 21 years, lack of fluency in English, evidence of thought disorder, delusions, hallucinations, or suicidal ideation. Caregivers: lack of fluency in English; and evidence of thought disorder, delusions, hallucinations, or suicidal ideation.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jennifer L. Steel, PhD
Organizational Affiliation
UPMC Departemnt of Surgery
Official's Role
Principal Investigator
Facility Information:
Facility Name
UPMC East
City
Monroeville
State/Province
Pennsylvania
ZIP/Postal Code
15146
Country
United States
Facility Name
The University of Pittsburgh's Medical Center Passavant Hospital
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15213
Country
United States
Facility Name
University of Pittsburgh Medical Center Mercy
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15213
Country
United States
Facility Name
University of Pittsburgh's Medical Center Montefiore Hospital
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15213
Country
United States
Facility Name
UPMC Presbyterian
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15213
Country
United States
Facility Name
UPMC St. Margaret
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15215
Country
United States
Facility Name
UPMC Horizen
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15219
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
De-Identified Data may be shared with investigators who request data from the Primary Investigator
IPD Sharing Time Frame
Data will be available at the end of the study for up to one year.
IPD Sharing Access Criteria
Appropriate investigator credentials (MD, PhD) and request, and for up to one year after study completion
Citations:
PubMed Identifier
35083809
Citation
Steel JL, Amin A, Peyser T, Olejniczak D, Antoni M, Carney M, Tillman E, Hecht CL, Pandya N, Miceli J, Reyes V, Nilsen M, Johnson J, Kiefer G, Pappu B, Zandberg DP, Geller DA. The benefits and consequences of the COVID-19 pandemic for patients diagnosed with cancer and their family caregivers. Psychooncology. 2022 Jun;31(6):1003-1012. doi: 10.1002/pon.5891. Epub 2022 Feb 1.
Results Reference
derived
PubMed Identifier
33556589
Citation
Steel JL, Reyes V, Zandberg DP, Nilsen M, Terhorst L, Richards G, Pappu B, Kiefer G, Johnson J, Antoni M, Vodovotz Y, Spring M, Walker J, Geller DA. The next generation of collaborative care: The design of a novel web-based stepped collaborative care intervention delivered via telemedicine for people diagnosed with cancer. Contemp Clin Trials. 2021 Jun;105:106295. doi: 10.1016/j.cct.2021.106295. Epub 2021 Feb 5.
Results Reference
derived

Learn more about this trial

Web-based Collaborative Care Intervention Study

We'll reach out to this number within 24 hrs